Agentix Corp.
Agentix Corp. (AGTX): 2 pipeline candidates · ~2 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.4 months
D/E -1.00 · 0% dilution
Lead: Phase 1
2 candidates
N/A
N/A
A transparent, data-derived signal for Agentix Corp.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$681K
Cash
$6K
Quarterly Burn
$8K
Runway
2.4 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| AGTX-2003 (RTI-1092769) | Preclinical |
| AGTX-2004 (DBPR211) | Phase 1 |
Frequently asked questions
How many drug candidates are in Agentix Corp.'s pipeline?
Agentix Corp. (AGTX) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Agentix Corp.'s lead drug candidate?
Agentix Corp.'s most advanced tracked candidate is AGTX-2003 (RTI-1092769) (Preclinical) for Obesity and non-alcoholic fatty liver disease (NAFLD).
What is Agentix Corp.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Agentix Corp. has approximately 2.4 months of cash runway.
What is Agentix Corp.'s market capitalization?
Agentix Corp.'s market capitalization is approximately $681K.
Who is the CEO of Agentix Corp.?
Mr. Riazul Huda is the chief executive officer of Agentix Corp. (AGTX).
Get the full picture on Agentix Corp.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.